For a diagnosed asthmatic patient presenting with breathlessness, the initial treatment would involve administering high doses of a rapid-acting inhaled bronchodilator like salbutamol every 20 minutes for the first hour. If the patient does not see adequate improvement, ipratropium bromide would be added. Systemic corticosteroids like prednisolone would also be prescribed if the exacerbation is severe or not responding to initial bronchodilator therapy, to reduce inflammation and control the attack.
This document discusses various inhalation delivery systems used for asthma and COPD treatment. It describes pressurized metered dose inhalers, dry powder inhalers, nebulizers, and the drugs commonly used with each. The advantages and disadvantages of each delivery system are provided. For asthma, inhaled glucocorticoids, long-acting beta-agonists, cromolyn, and short-acting beta-agonists are discussed. For COPD, long-acting beta-agonists, anticholinergics like tiotropium, and inhaled corticosteroids alone or in combination are covered. Proper inhaler technique is emphasized for optimal treatment.
Respiratory Distress & Status asthmaticus in Paediatricsmeducationdotnet
1. Respiratory distress is a clinical condition of increased respiratory rate and accessory muscle use that can progress to respiratory failure. Common causes include central or peripheral airway obstruction, diffuse lung damage, or issues with the respiratory pump.
2. Management involves ABCDE emergency care and non-invasive respiratory support with oxygen, nasal CPAP, or BiPAP if not in impending respiratory failure. The goal is restoring gas exchange with minimal complications by addressing underlying causes.
3. Mechanical ventilation may be needed for severe hypoxemia or hypercarbia from pneumonia, or when other systemic dysfunction jeopardizes gas exchange. Hypoxemia is prioritized over hypercarbia.
Asthma is a chronic inflammatory lung disease characterized by episodic difficulty breathing. It affects over 262 million people globally. The disease involves inflammation of the airways, bronchospasm, and increased mucus production. Common triggers include allergens, pollution, and exercise. Diagnosis involves pulmonary function tests showing variable expiratory airflow limitation. Treatment aims to control symptoms and prevent exacerbations with inhaled corticosteroids, bronchodilators, and oral corticosteroids for acute exacerbations. Proper inhaler technique and adherence to treatment are important for effective asthma management.
This document provides information on inhaler therapy for respiratory conditions. It discusses the different types of inhalation devices including dry powder inhalers, metered dose inhalers, metered dose inhalers with spacers, and nebulizers. It covers the use, advantages, and disadvantages of each device. The document also reviews common medications used in inhalers such as beta-2 agonists, glucocorticosteroids, and anticholinergics. Brand names and doses of these medications are listed.
This document defines asthma exacerbations and outlines factors for assessing exacerbation risk and severity. It also provides guidelines for asthma management, including initial treatment of exacerbations, adjusting controller medications, the roles of different medication classes, and the importance of patient education and proper inhaler technique. Key factors that increase exacerbation risk include poor asthma control, severity, lung function, comorbidities, psychosocial issues, and prior severe attacks. Treatment involves relievers, adjusting controllers based on symptoms and lung function, and sometimes oral corticosteroids.
This document provides guidance on administering asthma medications to children of varying ages. It discusses the differences between quick-relief and everyday controller medications and describes proper use of common delivery methods like metered dose inhalers, dry powder inhalers, and nebulizers. The document explains how to use masks and spacers to improve medication delivery and outlines how to administer medications based on a child's age, noting common errors and how to correct them. The goal is to help child care providers properly administer inhaled asthma medications and ensure children's medications are controlled.
This document discusses the management of persistent asthma using a single inhaler for both maintenance and rescue treatment (SMART). It provides background on asthma as a global health problem, describes current treatment approaches, and outlines the SMART method. With SMART, patients use a single inhaler containing budesonide and formoterol for both regular maintenance doses and additional as-needed doses to control symptoms. This approach aims to improve asthma control with one easy-to-use inhaler instead of multiple devices.
This document discusses various inhalation delivery systems used for asthma and COPD treatment. It describes pressurized metered dose inhalers, dry powder inhalers, nebulizers, and the drugs commonly used with each. The advantages and disadvantages of each delivery system are provided. For asthma, inhaled glucocorticoids, long-acting beta-agonists, cromolyn, and short-acting beta-agonists are discussed. For COPD, long-acting beta-agonists, anticholinergics like tiotropium, and inhaled corticosteroids alone or in combination are covered. Proper inhaler technique is emphasized for optimal treatment.
Respiratory Distress & Status asthmaticus in Paediatricsmeducationdotnet
1. Respiratory distress is a clinical condition of increased respiratory rate and accessory muscle use that can progress to respiratory failure. Common causes include central or peripheral airway obstruction, diffuse lung damage, or issues with the respiratory pump.
2. Management involves ABCDE emergency care and non-invasive respiratory support with oxygen, nasal CPAP, or BiPAP if not in impending respiratory failure. The goal is restoring gas exchange with minimal complications by addressing underlying causes.
3. Mechanical ventilation may be needed for severe hypoxemia or hypercarbia from pneumonia, or when other systemic dysfunction jeopardizes gas exchange. Hypoxemia is prioritized over hypercarbia.
Asthma is a chronic inflammatory lung disease characterized by episodic difficulty breathing. It affects over 262 million people globally. The disease involves inflammation of the airways, bronchospasm, and increased mucus production. Common triggers include allergens, pollution, and exercise. Diagnosis involves pulmonary function tests showing variable expiratory airflow limitation. Treatment aims to control symptoms and prevent exacerbations with inhaled corticosteroids, bronchodilators, and oral corticosteroids for acute exacerbations. Proper inhaler technique and adherence to treatment are important for effective asthma management.
This document provides information on inhaler therapy for respiratory conditions. It discusses the different types of inhalation devices including dry powder inhalers, metered dose inhalers, metered dose inhalers with spacers, and nebulizers. It covers the use, advantages, and disadvantages of each device. The document also reviews common medications used in inhalers such as beta-2 agonists, glucocorticosteroids, and anticholinergics. Brand names and doses of these medications are listed.
This document defines asthma exacerbations and outlines factors for assessing exacerbation risk and severity. It also provides guidelines for asthma management, including initial treatment of exacerbations, adjusting controller medications, the roles of different medication classes, and the importance of patient education and proper inhaler technique. Key factors that increase exacerbation risk include poor asthma control, severity, lung function, comorbidities, psychosocial issues, and prior severe attacks. Treatment involves relievers, adjusting controllers based on symptoms and lung function, and sometimes oral corticosteroids.
This document provides guidance on administering asthma medications to children of varying ages. It discusses the differences between quick-relief and everyday controller medications and describes proper use of common delivery methods like metered dose inhalers, dry powder inhalers, and nebulizers. The document explains how to use masks and spacers to improve medication delivery and outlines how to administer medications based on a child's age, noting common errors and how to correct them. The goal is to help child care providers properly administer inhaled asthma medications and ensure children's medications are controlled.
This document discusses the management of persistent asthma using a single inhaler for both maintenance and rescue treatment (SMART). It provides background on asthma as a global health problem, describes current treatment approaches, and outlines the SMART method. With SMART, patients use a single inhaler containing budesonide and formoterol for both regular maintenance doses and additional as-needed doses to control symptoms. This approach aims to improve asthma control with one easy-to-use inhaler instead of multiple devices.
Asthma is a chronic inflammatory disorder of the airways causing airflow obstruction
and recurrent episodes of
wheezing,
breathlessness,
chest tightness and
coughing.
Chronic inflammatory airway disease associated with increased airway responsiveness and reversible airway obstruction.
It can present at any age; majority of cases diagnosed in childhood
Most of them become asymptomatic by adolescence
Disease severity rarely progresses; patients with severe asthma have it at the onset.
FACTORS EFFECTING ASTHMA:
The inside lining of the airways becomes red and swollen (inflammation)
Extra mucus (sticky fluid) may be produced
The muscle around the airways tightens
(bronchoconstriction)
DIAGNOSIS:
Pulse oximetry and ABG analysis
Chest Xray
Blood Test
Peak Flow meter + Spirometry- PEFR + FEV1 decrease
PEFR + FEV1 increase >15% after β agonist inhalation
Skin Testing
This document discusses asthma, including its symptoms, diagnosis, treatment, and management. It defines asthma and an asthma exacerbation. It outlines the medical history and symptoms to assess in a patient. It describes lung function testing, classifications of asthma severity, and long-term control versus quick relief medications. It provides details on common asthma medications and inhaler devices. It offers guidance on treating mild, moderate, and severe asthma exacerbations. It discusses developing an asthma action plan and the goals of treatment and management.
Asthma Signs and Symptoms, Severity Classification, GINA and ATS Classification, Step-up Management of Chronic Asthma and Management of Acute Exacerbation of Asthma
1) The document discusses various cases of patients with respiratory diseases like asthma and COPD and evaluates their suitability for different drug delivery systems like metered dose inhalers, dry powder inhalers, and nebulizers.
2) It also discusses guidelines for using nebulizers for long-term or "maintenance" treatment of respiratory diseases at home, including patient selection criteria, drug choices, safety considerations, and review procedures.
3) Key factors in determining the need for home nebulization include a patient's ability to properly use handheld inhalers, the severity of their symptoms, comorbidities, and the need for high drug doses. Proper patient education and safety protocols are important for
Chronic Obstructive Pulmonary Disease (COPD) called as Chronic Obstructive Airway Disease.
COPD is characterized by difficulty in exhaling air.
It is slowly progressive disease and irreversible.
The most common cause of COPD is Cigarette Smoking.
COPD may include diseases that cause airflow obstruction (eg., Emphysema, Chronic Bronchitis) or combination of these disorders.
- Coughing is a protective reflex action that aims to clear irritants from the airway. Most coughs are caused by viral upper respiratory tract infections and will improve on their own within a few days.
- Coughs can be classified as productive (with sputum) or unproductive (dry). Productive coughs may indicate bacterial infection. Coughs lasting over 2 weeks should be referred to a doctor.
- Treatment depends on cough type but includes suppressants for dry coughs and expectorants for productive coughs. Demulcents soothe the throat. While evidence for efficacy is limited, cough remedies provide relief for many through placebo effect.
The nasal oxygen catheter consists of a plastic tube with a loop and two prongs at one end to insert into the nostrils to deliver oxygen. The other end connects to an oxygen source. It allows for speech and nutrition by delivering oxygen to the nasopharynx while leaving the oral cavity free.
The metered dose inhaler consists of a canister with medicine and propellant inside that delivers an aerosol when pressed. The patient breathes out, places their mouth on the inhaler, presses the canister to release a puff, and inhales deeply to treat asthma attacks or for long-term maintenance therapy.
Dry powder inhalers contain medication in a capsule inserted into the device. Rot
1) Inhalers deliver medication directly to the lungs through aerosol particles between 1-5 micrometers in size for optimal deposition.
2) Common inhaler devices include metered dose inhalers, dry powder inhalers, nebulizers, and soft mist inhalers. Each have advantages and disadvantages related to portability, ease of use, and drug deposition.
3) New connected inhalers like Adhero are being developed to track patient usage through sensors and smartphone apps to improve medication adherence and clinical outcomes.
Agents used for sedation in pediatric dentistry Aya Adel
This document discusses various agents used for sedation. It begins by defining sedation and sedative drugs. There are two main types of sedation: conscious and unconscious. The document then discusses different classes of sedative drugs including gases like nitrous oxide and desflurane, antihistamines like hydroxyzine and diphenhydramine, hypnotic drugs like barbiturates, benzodiazepines, and chloral hydrate, and narcotics like fentanyl and meperidine. It provides details on the mechanism of action, dosages, side effects, and drug combinations for conscious sedation for many of the discussed sedative agents.
The document provides guidelines for the management of COPD. It outlines the goals of COPD management, which include preventing disease progression, relieving symptoms, and improving exercise tolerance. It describes components of management including assessing disease, reducing risk factors, managing stable COPD, and managing acute exacerbations. For stable COPD, it recommends a stepwise treatment approach based on disease severity involving bronchodilators, inhaled corticosteroids, rehabilitation, oxygen therapy, and occasionally surgery. It provides guidance on treating exacerbations with bronchodilators, corticosteroids, and antibiotics as needed.
The document discusses drugs related to the respiratory system. It covers several classes of drugs including bronchodilators, corticosteroids, antihistamines, and cough preparations. Bronchodilators such as beta-2 agonists, antimuscarinic agents, and xanthine derivatives are used to relieve bronchospasm. Corticosteroids are used to reduce inflammation and include inhaled and systemic formulations. The document provides examples of drugs in each class, their mechanisms of action, dosages, and adverse effects.
Island Gate General Trading LLC initially conducted its business in 2004; serving important markets such as industrial, consumer electronics, electrical, and health care. From that humble beginning, the company has come a long way in terms of total business development and expansion.
This document discusses different types of inhalation devices used to deliver asthma medications, including their mechanisms and proper use. The main types covered are metered dose inhalers (MDIs), dry powder inhalers (DPIs), and nebulizers. MDIs consist of a canister, metering valve and actuator to deliver precise doses. DPIs require faster inhalation to disperse dry powder medication. Nebulizers use compressed air to deliver medication in a mist over 5-15 minutes. Proper technique is important for all devices to ensure effective delivery of medication to the lungs.
This document provides information on the management of acute exacerbations of asthma. It defines an exacerbation as an increase in cough, wheeze and breathlessness. Exacerbations are classified as mild, moderate or severe/life-threatening based on symptoms and measurements like peak expiratory flow rate (PEFR). For mild exacerbations, short-acting beta agonists are recommended. For moderate/severe exacerbations, additional treatments like oral corticosteroids and oxygen are used. Life-threatening exacerbations require emergency treatments including supplemental oxygen, nebulized bronchodilators and injectable medications, and patients may require intensive care or ventilation if symptoms do not improve. Clinical signs, response to treatment and measurements are used to
This document discusses challenges in diagnosing and managing asthma. It addresses managing the diagnosis, the patient's mindset, treatment, and non-adherence. Regarding diagnosis, it emphasizes listening to patients, using models to explain inflammation, and observing children at rest and exercise. Managing the patient's mind involves addressing denial of the condition and concerns about medications. Treatment focuses on the advantages of inhaled therapies over oral medications. Non-adherence can be addressed through once-daily dosing, using peak flow meters, and taking comorbidities seriously. The difficult asthmatic may just need re-education on airway structure and treatment.
This document provides information on the management of asthma in both hospital and outpatient settings. It begins with definitions and descriptions of asthma. It then discusses diagnosis, including taking a medical history and using peak expiratory flow measurements. Physical exam findings are outlined. Management goals are defined as good control of symptoms and lung function. Education of patients is emphasized. Criteria for admission to the hospital or seeking medical attention are provided. Details are given on treatment in hospital and outpatient follow up care.
The document discusses the pathogenesis of bacterial infection, including how bacteria interact with the host and cause disease. It describes factors that determine bacterial virulence like toxins, invasiveness, and the ability to evade the immune system. The document outlines Koch's postulates for determining the causative agent of a disease and notes exceptions where these postulates do not always apply. It also summarizes some key terms used in pathogenesis like infection, pathogenicity, and virulence factors. Specific examples of bacterial toxins that contribute to disease are discussed.
This document provides an overview and guidelines for choosing antibiotics. It discusses collecting cultures before starting antibiotics and ensuring appropriate dosing. Common antibiotics are reviewed including beta-lactams like penicillins, cephalosporins, and carbapenems as well as quinolones, macrolides, and metronidazole. Specific coverage and cautions are highlighted. A case of possible osteomyelitis in a diabetic man with leg cellulitis is presented. Factors to consider when selecting antibiotics include patient history, location of infection, and likely pathogens.
Asthma is a chronic inflammatory disorder of the airways causing airflow obstruction
and recurrent episodes of
wheezing,
breathlessness,
chest tightness and
coughing.
Chronic inflammatory airway disease associated with increased airway responsiveness and reversible airway obstruction.
It can present at any age; majority of cases diagnosed in childhood
Most of them become asymptomatic by adolescence
Disease severity rarely progresses; patients with severe asthma have it at the onset.
FACTORS EFFECTING ASTHMA:
The inside lining of the airways becomes red and swollen (inflammation)
Extra mucus (sticky fluid) may be produced
The muscle around the airways tightens
(bronchoconstriction)
DIAGNOSIS:
Pulse oximetry and ABG analysis
Chest Xray
Blood Test
Peak Flow meter + Spirometry- PEFR + FEV1 decrease
PEFR + FEV1 increase >15% after β agonist inhalation
Skin Testing
This document discusses asthma, including its symptoms, diagnosis, treatment, and management. It defines asthma and an asthma exacerbation. It outlines the medical history and symptoms to assess in a patient. It describes lung function testing, classifications of asthma severity, and long-term control versus quick relief medications. It provides details on common asthma medications and inhaler devices. It offers guidance on treating mild, moderate, and severe asthma exacerbations. It discusses developing an asthma action plan and the goals of treatment and management.
Asthma Signs and Symptoms, Severity Classification, GINA and ATS Classification, Step-up Management of Chronic Asthma and Management of Acute Exacerbation of Asthma
1) The document discusses various cases of patients with respiratory diseases like asthma and COPD and evaluates their suitability for different drug delivery systems like metered dose inhalers, dry powder inhalers, and nebulizers.
2) It also discusses guidelines for using nebulizers for long-term or "maintenance" treatment of respiratory diseases at home, including patient selection criteria, drug choices, safety considerations, and review procedures.
3) Key factors in determining the need for home nebulization include a patient's ability to properly use handheld inhalers, the severity of their symptoms, comorbidities, and the need for high drug doses. Proper patient education and safety protocols are important for
Chronic Obstructive Pulmonary Disease (COPD) called as Chronic Obstructive Airway Disease.
COPD is characterized by difficulty in exhaling air.
It is slowly progressive disease and irreversible.
The most common cause of COPD is Cigarette Smoking.
COPD may include diseases that cause airflow obstruction (eg., Emphysema, Chronic Bronchitis) or combination of these disorders.
- Coughing is a protective reflex action that aims to clear irritants from the airway. Most coughs are caused by viral upper respiratory tract infections and will improve on their own within a few days.
- Coughs can be classified as productive (with sputum) or unproductive (dry). Productive coughs may indicate bacterial infection. Coughs lasting over 2 weeks should be referred to a doctor.
- Treatment depends on cough type but includes suppressants for dry coughs and expectorants for productive coughs. Demulcents soothe the throat. While evidence for efficacy is limited, cough remedies provide relief for many through placebo effect.
The nasal oxygen catheter consists of a plastic tube with a loop and two prongs at one end to insert into the nostrils to deliver oxygen. The other end connects to an oxygen source. It allows for speech and nutrition by delivering oxygen to the nasopharynx while leaving the oral cavity free.
The metered dose inhaler consists of a canister with medicine and propellant inside that delivers an aerosol when pressed. The patient breathes out, places their mouth on the inhaler, presses the canister to release a puff, and inhales deeply to treat asthma attacks or for long-term maintenance therapy.
Dry powder inhalers contain medication in a capsule inserted into the device. Rot
1) Inhalers deliver medication directly to the lungs through aerosol particles between 1-5 micrometers in size for optimal deposition.
2) Common inhaler devices include metered dose inhalers, dry powder inhalers, nebulizers, and soft mist inhalers. Each have advantages and disadvantages related to portability, ease of use, and drug deposition.
3) New connected inhalers like Adhero are being developed to track patient usage through sensors and smartphone apps to improve medication adherence and clinical outcomes.
Agents used for sedation in pediatric dentistry Aya Adel
This document discusses various agents used for sedation. It begins by defining sedation and sedative drugs. There are two main types of sedation: conscious and unconscious. The document then discusses different classes of sedative drugs including gases like nitrous oxide and desflurane, antihistamines like hydroxyzine and diphenhydramine, hypnotic drugs like barbiturates, benzodiazepines, and chloral hydrate, and narcotics like fentanyl and meperidine. It provides details on the mechanism of action, dosages, side effects, and drug combinations for conscious sedation for many of the discussed sedative agents.
The document provides guidelines for the management of COPD. It outlines the goals of COPD management, which include preventing disease progression, relieving symptoms, and improving exercise tolerance. It describes components of management including assessing disease, reducing risk factors, managing stable COPD, and managing acute exacerbations. For stable COPD, it recommends a stepwise treatment approach based on disease severity involving bronchodilators, inhaled corticosteroids, rehabilitation, oxygen therapy, and occasionally surgery. It provides guidance on treating exacerbations with bronchodilators, corticosteroids, and antibiotics as needed.
The document discusses drugs related to the respiratory system. It covers several classes of drugs including bronchodilators, corticosteroids, antihistamines, and cough preparations. Bronchodilators such as beta-2 agonists, antimuscarinic agents, and xanthine derivatives are used to relieve bronchospasm. Corticosteroids are used to reduce inflammation and include inhaled and systemic formulations. The document provides examples of drugs in each class, their mechanisms of action, dosages, and adverse effects.
Island Gate General Trading LLC initially conducted its business in 2004; serving important markets such as industrial, consumer electronics, electrical, and health care. From that humble beginning, the company has come a long way in terms of total business development and expansion.
This document discusses different types of inhalation devices used to deliver asthma medications, including their mechanisms and proper use. The main types covered are metered dose inhalers (MDIs), dry powder inhalers (DPIs), and nebulizers. MDIs consist of a canister, metering valve and actuator to deliver precise doses. DPIs require faster inhalation to disperse dry powder medication. Nebulizers use compressed air to deliver medication in a mist over 5-15 minutes. Proper technique is important for all devices to ensure effective delivery of medication to the lungs.
This document provides information on the management of acute exacerbations of asthma. It defines an exacerbation as an increase in cough, wheeze and breathlessness. Exacerbations are classified as mild, moderate or severe/life-threatening based on symptoms and measurements like peak expiratory flow rate (PEFR). For mild exacerbations, short-acting beta agonists are recommended. For moderate/severe exacerbations, additional treatments like oral corticosteroids and oxygen are used. Life-threatening exacerbations require emergency treatments including supplemental oxygen, nebulized bronchodilators and injectable medications, and patients may require intensive care or ventilation if symptoms do not improve. Clinical signs, response to treatment and measurements are used to
This document discusses challenges in diagnosing and managing asthma. It addresses managing the diagnosis, the patient's mindset, treatment, and non-adherence. Regarding diagnosis, it emphasizes listening to patients, using models to explain inflammation, and observing children at rest and exercise. Managing the patient's mind involves addressing denial of the condition and concerns about medications. Treatment focuses on the advantages of inhaled therapies over oral medications. Non-adherence can be addressed through once-daily dosing, using peak flow meters, and taking comorbidities seriously. The difficult asthmatic may just need re-education on airway structure and treatment.
This document provides information on the management of asthma in both hospital and outpatient settings. It begins with definitions and descriptions of asthma. It then discusses diagnosis, including taking a medical history and using peak expiratory flow measurements. Physical exam findings are outlined. Management goals are defined as good control of symptoms and lung function. Education of patients is emphasized. Criteria for admission to the hospital or seeking medical attention are provided. Details are given on treatment in hospital and outpatient follow up care.
The document discusses the pathogenesis of bacterial infection, including how bacteria interact with the host and cause disease. It describes factors that determine bacterial virulence like toxins, invasiveness, and the ability to evade the immune system. The document outlines Koch's postulates for determining the causative agent of a disease and notes exceptions where these postulates do not always apply. It also summarizes some key terms used in pathogenesis like infection, pathogenicity, and virulence factors. Specific examples of bacterial toxins that contribute to disease are discussed.
This document provides an overview and guidelines for choosing antibiotics. It discusses collecting cultures before starting antibiotics and ensuring appropriate dosing. Common antibiotics are reviewed including beta-lactams like penicillins, cephalosporins, and carbapenems as well as quinolones, macrolides, and metronidazole. Specific coverage and cautions are highlighted. A case of possible osteomyelitis in a diabetic man with leg cellulitis is presented. Factors to consider when selecting antibiotics include patient history, location of infection, and likely pathogens.
This document discusses various idiopathic interstitial pneumonias (IIPs), including their definitions, histological features, radiographic appearances, treatments, and prognoses. It covers common IIPs such as idiopathic pulmonary fibrosis (IPF), nonspecific interstitial pneumonia (NSIP), desquamative interstitial pneumonia (DIP), respiratory bronchiolitis-associated interstitial lung disease (RB-ILD), acute interstitial pneumonia (AIP), and cryptogenic organizing pneumonia (COP). Lung biopsy is an important tool to distinguish between IIPs and make treatment decisions, but larger tissue samples are often needed due to sampling errors with transbronchial biopsies
This document provides an overview of various infectious diseases caused by bacteria, viruses, mycetes, and parasites. It describes common bacterial infections from staphylococci, streptococci, pneumococci, neisseria, and more. It also summarizes viral diseases caused by DNA viruses including poxviruses, herpesviruses, adenoviruses, papovaviruses, and parvoviruses. The document provides detailed information on infectious disease symptoms, transmission routes, locations of infection in the body, and potential complications.
This document discusses antifungal drugs used to treat fungal infections. It covers several classes of antifungals including polyenes like amphotericin B and nystatin that damage fungal cell membranes, azoles like fluconazole and itraconazole that inhibit ergosterol synthesis, echinocandins like caspofungin that inhibit cell wall synthesis, and other antifungals such as flucytosine and allylamines. Each drug's mechanism of action, indications, dosage, administration route, efficacy, side effects, and drug interactions are described. The document provides an in-depth overview of antifungal drug properties and use in treating various fungal diseases
This document outlines plans for Phase II of the GNP (Good Nebulization Practice) program which aims to educate doctors, paramedics, patients, and chemists on best practices for nebulization. Key goals are to reach 2000 intensivists in ICUs, translate materials to regional languages for 10,000 doctors, and increase outreach to 5000 chemists. The Phase II plan includes expanding existing GNP clinic and kit services, launching regional language nebulization corners, meetings focused on scientific and practical aspects, and utilizing digital tools and video demonstrations. New and existing customers will be categorized and provided tailored education and resources to improve nebulization practices.
1) The document discusses how asthma management can provide great opportunities for family doctors and general practitioners to treat patients and grow their practices. Asthma is very common, affecting 1 in 10 patients, and most patients prefer treatment from their family doctor over a chest physician.
2) The key to a successful asthma practice is proper diagnosis, treatment, simplifying the treatment plan for patients, and effective communication. Proper diagnosis can usually be made with a focused history and examination. Treatment involves both reliever and controller medications, with inhaled corticosteroids being the most effective controller.
3) With the right approach, family doctors can treat asthma as effectively as chest physicians. Regular use of inhaled corticosteroids
Does Over-Masturbation Contribute to Chronic Prostatitis.pptxwalterHu5
In some case, your chronic prostatitis may be related to over-masturbation. Generally, natural medicine Diuretic and Anti-inflammatory Pill can help mee get a cure.
Cell Therapy Expansion and Challenges in Autoimmune DiseaseHealth Advances
There is increasing confidence that cell therapies will soon play a role in the treatment of autoimmune disorders, but the extent of this impact remains to be seen. Early readouts on autologous CAR-Ts in lupus are encouraging, but manufacturing and cost limitations are likely to restrict access to highly refractory patients. Allogeneic CAR-Ts have the potential to broaden access to earlier lines of treatment due to their inherent cost benefits, however they will need to demonstrate comparable or improved efficacy to established modalities.
In addition to infrastructure and capacity constraints, CAR-Ts face a very different risk-benefit dynamic in autoimmune compared to oncology, highlighting the need for tolerable therapies with low adverse event risk. CAR-NK and Treg-based therapies are also being developed in certain autoimmune disorders and may demonstrate favorable safety profiles. Several novel non-cell therapies such as bispecific antibodies, nanobodies, and RNAi drugs, may also offer future alternative competitive solutions with variable value propositions.
Widespread adoption of cell therapies will not only require strong efficacy and safety data, but also adapted pricing and access strategies. At oncology-based price points, CAR-Ts are unlikely to achieve broad market access in autoimmune disorders, with eligible patient populations that are potentially orders of magnitude greater than the number of currently addressable cancer patients. Developers have made strides towards reducing cell therapy COGS while improving manufacturing efficiency, but payors will inevitably restrict access until more sustainable pricing is achieved.
Despite these headwinds, industry leaders and investors remain confident that cell therapies are poised to address significant unmet need in patients suffering from autoimmune disorders. However, the extent of this impact on the treatment landscape remains to be seen, as the industry rapidly approaches an inflection point.
Adhd Medication Shortage Uk - trinexpharmacy.comreignlana06
The UK is currently facing a Adhd Medication Shortage Uk, which has left many patients and their families grappling with uncertainty and frustration. ADHD, or Attention Deficit Hyperactivity Disorder, is a chronic condition that requires consistent medication to manage effectively. This shortage has highlighted the critical role these medications play in the daily lives of those affected by ADHD. Contact : +1 (747) 209 – 3649 E-mail : sales@trinexpharmacy.com
Kosmoderma Academy, a leading institution in the field of dermatology and aesthetics, offers comprehensive courses in cosmetology and trichology. Our specialized courses on PRP (Hair), DR+Growth Factor, GFC, and Qr678 are designed to equip practitioners with advanced skills and knowledge to excel in hair restoration and growth treatments.
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPsychoTech Services
A proprietary approach developed by bringing together the best of learning theories from Psychology, design principles from the world of visualization, and pedagogical methods from over a decade of training experience, that enables you to: Learn better, faster!
DECLARATION OF HELSINKI - History and principlesanaghabharat01
This SlideShare presentation provides a comprehensive overview of the Declaration of Helsinki, a foundational document outlining ethical guidelines for conducting medical research involving human subjects.
1. Acute Exacerbation Chronic or long
term
•Severe
•Short term
•Also known as attack
•High doses are required
•Mild
•Long term
Suitable therapy:
Nebulisation
Suitable therapy:
MDI + Spacer/ DPI
Asthma
Presentation
Asthma
2. Acute Exacerbation
Exacerbations of asthma (asthma attacks or acute asthma) are
episodes of progressive increase in shortness of breath, cough,
wheezing, or chest tightness, or some combination of these
symptoms.
Severe exacerbations are potentially life threatening, and their
treatment requires close supervision.
Patients with severe exacerbations should be encouraged to
see their physician promptly or, to proceed to the nearest clinic
or hospital that provides emergency access for patients with
acute asthma.
GINA 2006
Asthma
3. Acute asthma
All patients with asthma
irrespective of their
severity; are at a risk of
developing an acute
attack…
4. Acute asthma Symptoms
• Increased Breathlessness / Dysponea
[Difficulty in breathing]
• Increased Wheezing
[Whistling sound while exhaling]
• Increased Cough
[Often at night or after some exertion]
• Chest Tightness
5. Acute Asthma Signs
• Inability to complete a sentence
• Tachycardia [rapid heart beats]
• Tachypnea [rapid breathing]
• Accessory respiratory muscle use [around neck]
• Excessive sweating
• Cyanosis [blue discoloration of skin, lips in acute
severe cases]
6. Who is at risk?
• Previous hospitalization or “casualty visit” for asthma in
past year
• Currently using or have recently stopped using oral
steroids
• Not currently using preventive therapy
• Frequent use of salbutamol /terbutaline
• Emotional/ psychological component of asthma.
These patients require closer attention and
should be encouraged to seek urgent care
early in the course of their attacks.
7. Symptoms Mild- Moderate Severe- life threatening
Breathless On walking or talking At rest
Talks in Sentences / Phrases Words/
Unable to speak
Accessory muscles Usually not Usually
Central Cyanosis Absent Likely to be present
SaO2
[as measured by pulse
oximeter]
91-95%
OR
> 95%
< 90%
Pulse
rate
Adults <100-120 / min > 120 / min
Children <100-200 / min > 200 / min
Acute asthma classification
Refer to hospital
any patient with
features of
acute severe to life
threatening asthma
9. Nebulizer
Delivers a therapeutic dose
of the drug as an aerosol in
the form of respirable
particles within a short
period, 5-10 mins.
10. Why nebulized therapy.......
• Immediate relief is required which can be achieved only from
inhalation therapy.
• Targeted drug delivery.
• Easy to Use
• When High dose of medications are required.
• Does not require coordination between inspiration and actuation as
it uses normal tidal breathing.
• Patient who does not respond to regular treatment with oral or other
inhaled devices, may benefit.
• Critically ill patients, unable to co-ordinate with other inhaler
devices like MDI or Rotahaler , may benefit.
• Profitable
11. Advantages of nebulized therapy
Over Injectables
Targeted drug delivery
Lesser side effects
Non invasive / Painless
Easy to use
Over Orals
Targeted drug delivery
Lesser side effects
Faster onset of action
Very useful in acute cases
12. Nebulized therapy used for…
• Acute attacks of asthma
• Acute attacks of COPD
• Symptomatic relief of Croup
• Other respiratory diseases presenting with acute
bronchitis
• Rarely, at home, in mild-moderate acute asthma when
the patient can’t use other inhaler devices.
• Infants, children and elderly patients who can’t use other
inhaler devices.
14. JET nebulizer
• Based on compressed air technology.
• Widely used
• Economical
• Any form of liquid can be nebulized (including
suspensions).
15. Ultrasonic Nebulizer
• Based on high frequency sound waves technology.
• Finest mist and better deposition
• Not preferable for suspensions.
• Less noisy
• Costly, thus limits its use.
16. Parts of the Nebulizer
Nebulizer system consists of the following parts.
Tubing nebulization
Chamber
Mask/Mouthpiece
Compressor
• The compressor is the portable pump which provides power
for nebulizer.
• The nebulizer is the small chamber into which the liquid
medicine is put and through which the air is blown to make a
mist.
18. Important Aspects
Nebulization Time
• Time from starting
nebulization until
continuous nebulization
has ceased
• For bronchodilators it
should be <10 mins.
19. Important Aspects
Nebulization End point
• Patients should be
nebulize for about a
minute after ‘spluttering’
occurs
• Residual volume of 0.5 to
1 ml will always remain in
the nebulizer
20. Important Aspects
Driving gas flow rate
• Most jet nebulizers work
at a flow rate of 6-8 l/min
• Oxygen can be used if a
compressor is not
available.
22. Important Aspects
OR
Face Masks Mouthpiece
Prefer When Patient is …
•Too critical
•Unconscious
•Pediatric
Prefer When Patient is …
• Comfortable enough to hold the
mouthpiece
• Receiving anticholinergics
• Receiving Steroids
Do not talk while being nebulized
23. Management of mild / moderate
acute asthma
After brief history* and physical
examination…
*Rule out beta blocker or NSAID [aspirin] use, check for exposure
to strong trigger
24. Rapid Acting Bronchodilators
• Repeated administration of rapid-acting inhaled beta2-
agonists.
E.g. Salbutamol or Levosalbutamol respules /MDI
• Every 20 min for first 3 doses
• After the first hour, the dose of beta2-agonist required will
depend on the severity of the exacerbation.
25. Rapid Acting Bronchodilators
• Treatment should also be titrated depending upon the
individual patient response.
• No evidence to support the routine use of IV beta2
agonists.
NEBULIZED [Respules/
Respirator solution]
MDI + SPACER
Salbutamol
[Asthalin]
Adult 2.5-5 mg Adult 8-12 puffs per hour
Child 1.25 -2.5 mg Child 4-6 puffs per hour
Levosalbutamol
[Levolin]
Adult 0.63-1.25 mg Adult 4-6 puffs per hour
Child 0.31-0.63 mg Child 2-3 puffs per hour
26. • Many patients will be able to monitor their PEF after the
initiation of increased bronchodilator therapy.
• No additional medication is necessary if the rapid-acting
inhaled beta2-agonist produces a complete response
(PEF returns to greater than 80% of predicted or
personal best) and the response lasts for 3 to 4 hours.
Rapid Acting Bronchodilators
27. Additional bronchodilators
• In case of poor response to beta2 agonist therapy; add
nebulized ipratropium bromide.
• Available In Combination As Duolin Respules
• Ipratropium +beta2 agonist combination:
– Greater bronchodialation
– Shorter duration of admission
– Faster recovery
Bronchodilators Adults Children
Ipratropium 250 – 500 mcg 250 mcg
28. Duolin LD
The Dual Action Bronchodilator
Brand Composition Pack
Duolin Respules Levosalbutamol 0.63 mg + Ipratropium bromide
500 mcg/ 2.5 ml
2.5 ml
Brand Volume of solution Dosage - adults and adolescents (above
12 years of age)
Duolin Respules 1 Respule 1 respule 3-4 times a day
29. If patient has…
• Reduced distress
• Able to complete sentence
• Near normal Pulse rate/ respiratory rate
• No use of accessory muscles
• Improved Oxygen saturation
[>95%=Child / >90%=Adult]
Consider sending home
32. When?
• Initial bronchodilator therapy fails improvement
• Attack in patient already on oral steroids.
• Previous attacks required oral steroids.
Systemic Steroids
GINA 2008
Age Daily dose of prednisolone Treatment up to
<2 years 10 mg 3 days or until recovery
2-5 years 20 mg 3 days or until recovery
>5 years 30-40 mg 3 days or until recovery
adults 40-50 mg at least 5-7 days/until recovery
35. Combination of Bronchodilator &
Steroid
• Makes available both bronchodilator and steroids
• Targets different aspects of asthma, salbutamol
reverses the bronchoconstriction and budesonide
takes care of inflammation
• Reduces nebulisation time.
Budesal: (Salbutamol + Budesonide)
37. The First Anti inflammatory
corticosteroid + Bronchodilator
Nebulised Therapy
Brand Composition Pack
Budesal 0.5 mg Respules Salbutamol 2.5 mg +
Budesonide 0.5 mg
2.5 ml
Budesal 1 mg Respules Salbutamol 2.5 mg +
Budesonide 1 mg
2.5 ml
Brand Volume of
solution
Dosage Adults Dosage
Children
Budesal
0.5 mg
Respules
1-2
respules
1-2 respules(1
mg) twice daily
or 1 respule
thrice daily
1-2 respules(0.5
mg) twice daily
or 1 respule
thrice daily
Budesal 1 mg
Respules
1-2
respules
38. High dose rapid acting bronchodilator*
Salbutamol (Asthalin)/ levosalbutamol (Levolin)
Partial / no response…
Add ipratropium
In severe cases, one can directly start with duolin
Partial / no response…
Initiate Steroid therapy
Further treatment depends on severity of acute asthma & response to the initial treatment.
Summary so far…
39. If patient has…
• No distress
• Able to complete sentence
• Near normal Pulse rate/ respiratory rate
• No use of accessory muscles
• Oxygen saturation [>95%=Child / >90%=Adult]
• Improved lung function [greater than 80% of predicted or
personal best]
Consider sending home
40. If patient has…
• Poor Response to Therapy
• Severe symptoms
• Drowsiness
• Cyanosis
• Also if already, High Risk Patient
Refer to hospital / ICU….
41. Other bronchodilators…
Theophylline
• Much less effective than Salbutamol + Ipratropium
• Injectible should be used in hospital settings only, with
monitoring serum levels.
• Mainly used as an add on therapy for prevention.
[long acting oral preparation]
Adrenaline
• Not routinely indicated for asthma attacks; mainly
indicated for anaphylaxis.
42. Do’s
• Never delay transfer to hospital/ICU if necessary
• Try to check pulse oximeter saturations at every step
• Ensure the patient who has been hospitalized is
discharged with regular ICS.
• Ensure patient has written asthma action plan.
• Prevent future acute asthma attacks by prescribing
regular treatment with inhaled corticosteroid
[MDI/ DPI].
43. The story of asthma treatment
Traditional treatment
Occasional Relievers
Ideal treatment
Regular Controllers
i.e. ICS
44. Follow up after hospital discharge
• Review within 48 hours
• Monitor symptoms and PEF
• Check inhaler technique
• Modify treatment according to severity
• Follow up with chest physician at regular interval
45. Good Nebulizer practice: Cleaning
• Disassemble.
• Wash in warm water with detergent at least once a day.
• Carefully dry.
• The nebulizer should be run empty for a moment or two
before the next use.
46. Respule
• A “respule” is an ampoule containing the liquid drug to
be nebulized.
• It contains drug, which is prediluted and hence can be
used directly.
• The respule should be broken and the liquid drug
should be pored into the nebulization chamber.
• Respules are for inhalation use only.
• The solution should not be injected or swallowed.
47. Respirator Solution
• Respirator solution contains the drug to be nebulized in
concentrated form.
• Dilute the drug concentrate in a ratio of 1 part of drug
solution: 3 parts of normal saline (0.9% sodium chloride).
• Care should be taken that after diluting the fill volume
should not exceed of 2-4 ml.
• It is not recommended to use distilled water or tap water
contains certain elements which itself could irritate the
airways.